Relationship between WT1 gene mutation and prognosis of acute myeloid leukemia: a Meta-analysis

Objective\r\nTo summarize the relationship between WT1 gene mutation and prognosis of acute myeloid leukemia (AML).\r\n\r\n\r\nMethods\r\nThe related literatures were searched in PubMed, Google Scholar and Cochrane Library databases, and the deadline was April 2, 2018. The Meta-analysis was performed by using Review Manager 5.2 software.\r\n\r\n\r\nResults\r\nA total of 9 literatures were included. Meta analysis showed that for the pediatric AML patients, the overall survival (OS) time in the WT1 gene mutated group was shorter than that in the wild-type group (HR= 1.41, 95% CI 1.07-1.87, P= 0.01). For the total AML patients, the relapse-free survival (RFS) time in the WT1 gene mutated group was shorter than that in the wild-type group (HR= 2.21, 95% CI 1.15-3.93, P= 0.02), but there was no significant difference in OS and disease-free survival (DFS) time between the two groups (HR= 1.65, 95% CI 0.97-2.80, P= 0.06; HR= 0.46, 95% CI 0.08-2.57, P= 0.38). For the AML patients with normal karyotype and adult AML patients, there was no difference in OS time between the WT1 gene mutated group and wild-type group (HR= 2.66, 95% CI 0.57-12.31, P= 0.21; HR= 2.10, 95% CI 0.70-6.30, P= 0.18).\r\n\r\n\r\nConclusion\r\nWT1 gene mutation is a risk factor affecting OS of pediatric AML patients and RFS of general AML patients.\r\n\r\n\r\nKey words: \r\nLeukemia, myeloid, acute; Gene, WT1; Prognosis; Meta-analysis